$1.35B deal offers vindication, runway for Austin-based XBiotech

In September 2018, XBiotech's shares closed as low as $2.31. Now its shares are about $22 and the company is riding high after selling a dermatological drug candidate in a deal that could be worth as much as $1.35 billion. Here's why XBiotech CEO John Simard feels the major milestone is just the beginning.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 10, 2020 Category: Pharmaceuticals Authors: Paul Thompson Source Type: news